Medical Trial: Appraising Medical Trial Experiences of Rheumatoid Arthritis Patients

Rheumatoid Arthritis Clinical Trial

Official title:

Observational Clinical Trial Appraising Medical Trial Experiences of Rheumatoid Arthritis Patients Participating In Clinical Research

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05398471
• Other study ID #: 58103638
• Status: Not yet recruiting
• Start date: August 2024
• Est. completion date: August 2026

Study information

• Verified date: December 2023
• Source: Power Life Sciences Inc.
• Contact: Michael B Gill
• Phone: (415) 287-9919
• Email: bask[@]withpower.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Historically, participation in clinical trials has been highly skewed towards specific demographic groups. However, research identifying which trial attributes impact participation, in either positive or negative ways, is limited. This study invites participants to record a wide range of data on their clinical trial experience, with the goal being to identify factors which persistently limit patients' ability to participate in, or complete, a trial in which they were initially interested. This data will be analyzed through a range of demographic lenses, in hopes of discovering patterns which might improve the experience of future rheumatoid arthritis patients.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 500
• Est. completion date: August 2026
• Est. primary completion date: August 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient has been diagnosed with rheumatoid arthritis

• Patient has self-identified as planning to enroll in an interventional clinical trial

• Patient is 18 years old

Exclusion Criteria:

• ECOG score of 4

• Patient is pregnant

• Inability to perform regular electronic reporting

• Patient does not understand, sign, and return consent form

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Locations

Country	Name	City	State
United States	Power Life Sciences	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
Power Life Sciences Inc.

Country where clinical trial is conducted

United States, 

References & Publications (3)

Lansey DG, Hefka TA, Carducci MA, Kanarek NF. Problem Solving to Enhance Clinical Trial Participation Utilizing a Framework-Driven Approach. Clin Adv Hematol Oncol. 2020 Aug;18(8):468-476. — View Citation

McKinney M, Bell R, Samborski C, Attwood K, Dean G, Eakle K, Yu W, Edge S. Clinical Trial Participation: A Pilot Study of Patient-Identified Barriers. Clin J Oncol Nurs. 2021 Dec 1;25(6):647-654. doi: 10.1188/21.CJON.647-654. — View Citation

Michos ED, Van Spall HGC. Increasing representation and diversity in cardiovascular clinical trial populations. Nat Rev Cardiol. 2021 Aug;18(8):537-538. doi: 10.1038/s41569-021-00583-8. No abstract available. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Patient decides to enroll in clinical trial		3 Months
Primary	Patient remains in clinical trial to completion		12 months